**Listing of Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-3. (Canceled)

4. (Currently Amended) A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering ~~a therapeutically~~ an effective amount of ~~a GLP-1 molecule~~ a compound selected from the group consisting of Glucagon-Like Peptide-1 (GLP-1), GLP-1 analogs, and GLP-1-like peptides, to a patient suffering from diabetic cardiomyopathy.

5. (Currently Amended) The method ~~according to any one of~~ of claim ~~claims 1 through~~ 4, wherein the administration is continuous.

6. (Currently Amended) The method ~~according to any one of~~ of claim ~~claims 1 through~~ 4, wherein the administration is parenteral.

7. (Currently Amended) The method ~~according to any one of~~ of claim ~~claims 1 through 4~~, wherein said effective amount of ~~GLP-1~~ said compound is effective to cause a reduction in the plasma or heart norepinepherine level.

8-9. (Canceled)

10. (Currently Amended) The method of claim 6, ~~whereby the GLP-1 molecule~~ wherein said compound is administered in a dose of from about 0.1-10 pmol/kg/min.

11. (Currently Amended) The method of claim 4 ~~whereby the GLP-1 molecule~~ wherein said compound is administered subcutaneously in a dose of ~~from~~ about 0.5-50 pmol/kg/min.

12. (Currently Amended) The method of claim 4 ~~whereby the GLP-1 molecule~~ wherein said compound is administered in a dose of up to 10.0 nmol/kg.

13. (Canceled)

14. (Currently Amended) The method of claim ~~13~~ 4 ~~whereby the GLP-1 molecule~~ wherein said compound is administered intravenously in a dose of ~~from~~ about 0.1-10 pmol/kg/min.

15-16. (Canceled)

17. (New) The method of claim 4, wherein said compound is selected from the group consisting of GLP-1(1-37), GLP-1(1-36)$NH_2$, GLP-1(7-37), and GLP-1(7-36)$NH_2$.

18. (New) The method of claim 4, wherein said compound is a GLP-1 analog, and the Ala at position 8 of said GLP-1 analog is substituted with an amino acid selected from the group consisting of Ser and Thr.

19. (New) The method of claim 4, wherein said compound is a GLP-1 analog, and the Glu at position 9 of said GLP-1 analog is substituted with Asp.

20. (New) A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering a therapeutically effective amount of an exendin.

21. (New) The method of claim 20, wherein the administration is continuous.

22. (New) The method of claim 20, wherein the administration is parenteral.

23. (New) The method of claim 20, wherein said effective amount of the exendin is effective to cause a reduction in the plasma or heart norepinepherine level.

24. (New) The method of claim 20, wherein said exendin is exendin-3.

25. (New) The method of claim 20, wherein said exendin is exendin-4.

III.

26. (New) A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering an effective amount of a compound which activates a receptor for glucagon-like peptide-1 (GLP-1).

27. (New) The method of claim 26, wherein the administration is continuous.

28. (New) The method of claim 26, wherein the administration is parenteral.

29. (New) The method of claim 28, wherein the compound is administered in a dose of from about 0.1-10 pmol/kg/min.

30. (New) The method of claim 26, wherein said effective amount of said compound is effective to cause a reduction in the plasma or heart norepinepherine level.

31. (New) The method of claim 26, wherein said compound is administered subcutaneously in a dose of from about 0.5-50 pmol/kg/min.

32. (New) The method of claim 26, wherein said compound is administered in a dose of up to 10.0 nmol/kg.

33. (New) The method of claim 26, wherein said compound is administered intravenously in a dose of from about 0.1-10 pmol/kg/min.

34. (New) The method of claim 26, wherein said compound which activates a receptor for GLP-1 is an exendin

35. (New) The method of claim 34, wherein said exendin is exendin-3.

36. (New) The method of claim 34, wherein said exendin is exendin-4

37. (New) The method of claim 26, wherein said compound which activates a receptor for GLP-1 is selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1-like peptides.

38. (New) The method of claim 37, wherein said compound is a GLP-1 analog, and the Ala at position 8 of said GLP-1 analog is substituted with an amino acid selected from the group consisting of Ser and Thr.

39. (New) The method of claim 37, wherein said compound is a GLP-1 analog, and the Glu at position 9 of said GLP-1 analog is substituted with Asp.

40. (New) The method of claim 37, wherein said compound which activates a receptor for GLP-1 is selected from the group consisting of GLP-1(1-37), GLP-1(1-36)$NH_2$, GLP-1(7-37), and GLP-1(7-36)$NH_2$.